Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Glistening-free intraocular lens: my experience

Poster Details

First Author: M.Sharma INDIA

Co Author(s):    P. Matta   D. Nath   S. Ghai   R. Kumar Saxena     

Abstract Details



Purpose:

To evaluate the clinical outcomes of the single piece hydrophobic glistening free Envista intraocular lens (IOL).

Setting:

Private Cum Charitable Organization

Methods:

62 enVista IOLs were implanted successfully into 62 eyes. Microincision cataract surgery was performed using 2.2 mm incision and a wound assisted envista IOL implantation was carried out. Age of the patients varied from 49 to 72 years. Mean preoperative visual acuity was 6/24. Clinical examination was done at Day 1, Day 7, Day 14, 1.5 months and 3 months. Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), refraction, intraocular pressure measurement and slit lamp examination were done. Any complications or adverse events were noted.

Results:

Mean postoperative UCVA and BCVA was 6/12 and 6/9 respectively at day 1. Mean postoperative UCVA and BCVA as 6/9 and 6/6 p respectively at day 90. All eyes achieved a best corrected visual acuity of more than 6/12. No clinically discernible glistening were documented on slit lamp examination. There were no surface scratches, broken haptics or posterior capsular opacification. The implant opened very slowly and was very easy to implant.

Conclusions:

Initial results of the enVista IOL show good BCVA and no initial glistenings. Glistenings deserves and attention for better visual outcomes and more studies are needed to conclusively prove the benefits of glistening free IOLs. FINANCIAL INTEREST: NONE

Back to Poster listing